论文部分内容阅读
目的：验证拉司太特胶囊的临床疗效和探索一些新的适应症如治疗非小细胞肺癌、食管癌等。方法：采用以拉司太特为主的联合化疗治疗晚期恶性肿瘤１６０例，可评价者１３７例。结果：总有效率５５５％。对小细胞肺癌有效率７０４％，对非小细胞肺癌有效率２９５％，对恶性淋巴瘤有效率６９６％，对乳腺癌、食管癌和胃癌的有效率分别为４／７、３／５和２／４。剂量限制性毒性为骨髓抑制，消化道反应中度，对肝、肾功能无明显影响。影响疗效的因素分析显示初治者与复治者有效率相仿；并且在１１例曾用过静脉ＶＰ１６治疗者中，有效率６３６％；表明口服ＶＰ１６与既往使用过的化疗药无交叉耐药性。结论：以拉司太特为主的联合化疗疗效好，毒副反应可以耐受。
Objective: To verify the clinical efficacy of Lastet capsules and explore new indications such as the treatment of non-small cell lung cancer, esophageal cancer and so on. Methods: A total of 160 cases of advanced malignant tumors were treated with the combined chemotherapy of rasperidone and 137 cases were evaluated. Result: The total efficiency is 55.5%. Effective rate is 70.4% for small cell lung cancer, 29.5% for non-small cell lung cancer, 69.6% for malignant lymphoma, and 4/7 for breast cancer, esophageal cancer, and gastric cancer. 3/5 and 2/4. Dose-limiting toxicities were myelosuppression, moderate gastrointestinal reactions, and no significant effect on liver and kidney function. Analysis of the factors affecting the efficacy showed that the initial treatment and retreatment were effective; and in 11 patients who had used intravenous VP 16 treatment, the effective rate was 63.6%; indicating that oral VP 16 and the previously used chemotherapy The drug has no cross resistance. Conclusion: The combined chemotherapy with predominately Lastretide is effective and toxic and side effects can be tolerated.